Pharmaceutical use of trisaccharide compound in pulmonary hypertension
By using compounds with specific trisaccharide structures, the shortcomings of pulmonary hypertension treatment were addressed, achieving inhibition of vascular remodeling and muscle tissue formation, improving cardiac function, and reducing the symptoms and progression of pulmonary hypertension.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- NANKAI UNIV
- Filing Date
- 2025-12-30
- Publication Date
- 2026-07-09
AI Technical Summary
Existing treatments for pulmonary hypertension are not effective in curing the condition and do not directly address the vascular remodeling and vascular myotomy observed in patients, leaving a significant unmet need for treatment.
A trisaccharide compound was used to improve cardiac function by reducing cardiac hypertrophy, vascular revascularization, and vascular myotomy in a SU5416- and hypoxia-induced pulmonary hypertension model. This compound has a specific structural formula A and can form monovalent, divalent, or trivalent salts, and was prepared via synthetic methods.
It significantly reduces vascular reconstruction and vascular myotomy, improves cardiac function, reduces the progression and severity of pulmonary hypertension, and improves patients' physical activity and symptoms such as dyspnea.
Smart Images
Figure CN2025147202_09072026_PF_FP_ABST